论文部分内容阅读
本刊讯英国药品和健康产品管理局(MHRA)发布信息称,使用双膦酸盐时有极为罕见的(少于1/10 000例患者)外耳道骨坏死报道,主要与2年或以上的长期治疗有关。双膦酸盐用于治疗骨质疏松、Paget病以及作为某些癌症方案的一部分治疗,特别是治疗转移性骨癌和多发性骨髓瘤。不同的双膦酸盐具有不同的适应证。已在英国上市的双膦酸盐有:阿仑膦酸、伊班膦酸、帕米膦酸二钠、利塞膦酸钠、氯曲膦酸钠和唑来膦酸。良性特发性外耳道骨坏死是一种罕
According to the release of MHRA, there are very rare cases of osteonecrosis of the auditory canal (less than 1 in 10,000 patients) reported with bisphosphonates, mainly with long-term outcomes of 2 years or more Treatment related. Bisphosphonates are used in the treatment of osteoporosis, Paget’s disease and as part of the treatment of certain cancer regimens, especially for the treatment of metastatic bone cancer and multiple myeloma. Different bisphosphonates have different indications. Bisphosphonates that are already on the market in the United Kingdom are alendronic acid, ibandronic acid, disodium pamidronate, risedronate sodium, clotriphrine sodium and zoledronic acid. Benign idiopathic external auditory canal osteonecrosis is a rare